Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy

Journal of Liposome Research

Volumn 16, Issue 3, 2006, Pages 195-204

  Adamina, Michel ^a   Schumacher, Reto ^a   Zajac, Paul ^a   Weber, Walter P ^b   Rosenthal, Rachel ^a   Groeper, Célia ^a   Feder, Chantal ^a   Zurbriggen, Rinaldo ^c   Amacker, Mario ^c   Spagnoli, Giulio C ^a   Oertli, Daniel ^b   Heberer, Michael ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Pevion Biotech Ltd   (Switzerland)

Author keywords

Cancer vaccines; Liposomes; Melanoma immunotherapy; Virosomes

Indexed keywords

DRUG CARRIER; LIPOSOME; MELANOMA VACCINE; TUMOR ANTIGEN; VIROSOME;

CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOGENICITY; MELANOMA; PRIORITY JOURNAL; TREATMENT PLANNING;

CANCER VACCINES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LIPOSOMES; MELANOMA;

EID: 33748479012     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982100600848546     Document Type: Conference Paper

References (37)

1. Adamina, M., Bolli, M., et al. (2004). Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. Br. J. Cancer 90: 263-269.
2. Adamina, M., Daetwiler, S., et al. (2005a). Clinical applications of recombinant virus-based cancer immunotherapy. Expert. Opin. Biol. Ther. 5:1211-1224.
3. Adamina, M., Oertli, D. (2005b). Antigen specific active immunotherapy: lessons from the first decade. Swiss. Med. Wkly. 135:212-221.
4. Adamina, M., Schumacher, R., Spagnoli, G. C. (2006). Liposomes in Cancer Immunotherapy. In Gregoriadis, G., ed. Liposome Technology. New York: Taylor & Francis CRC Press. 3rd edition, Volume III: in press.
5. Albo, F., Cavazza, A., et al. (2004). Degradation of the tumor antigen epitope gp100(280-288) by fibroblast-associated enzymes abolishes specific immunorecognition. Biochim. Biophys. Acta 1671:59-69.
6. Amoscato, A. A., Prenovitz, D. A., Lotze, M. T. (1998). Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. 161:4023-4032.
7. Arkema, A., Huckriede, A., et al. (2000). Induction of cytotoxic T lymphocyte activity by fusionactive peptide-containing virosomes. Vaccine 18:1327-1333.
8. Balch, C. M., Buzaid, A. C., et al. (2001). Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19:3635-3648.
9. Banchereau, J., Palucka, A. K., et al. (2001). Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451-6458.
10. Cavazza, A., Adamina, M., et al. (2004). Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. Clin. Immunol. 111:252-261.
11. Coley, W. B. (1893). The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am. J. Med. Sci. 105:487-511.
12. Copland, M. J., Baird, M. A., et al. (2003). Liposomal delivery of antigen to human dendritic cells. Vaccine 21:883-890.
13. Dudley, M. E., Wunderlich, J. R., et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854.
14. Durrer, P., Gluck, U., et al. (2003). Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21:4328-4334.
15. Figdor, C. G., de V. I., et al. (2004). Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475-480.
16. Gluck, R., Moser, C., Metcalfe, I. C. (2004). Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert. Opin. Biol. Ther. 4:1139-1145.
17. Hodge, J. W., Grosenbach, D. W., Schlom, J. (2002). Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and antitumor immunity. Cancer Detect. Prev. 26:275-291.
18. Kawamura, K., Kadowaki, N., et al. (2006). Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity. J. Immunother. 29:165-174.
19. Lowe, D. B., Shearer, M. H., Kennedy, R. C. (2006). DNA vaccines: Successes and limitations in cancer and infectious disease. J. Cell Biochem. 98:235-242.
20. Mocellin, S., Rossi, C. R., et al. (2003). Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochim. Biophys. Acta 1653:61-71.
21. Novellino, L., Castelli, C., Parmiani, G. (2005). A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54:187-207.
22. O'Hagan, D. T., Valiante, N. M. (2003). Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2:727-735.
23. Oertli, D., Marti, W. R., et al. (2002). Rapid induction of specific cytotoxic T lymphocytes against melanoma- associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum. Gene Ther. 13:569-575.
24. Parmiani, G., Castelli, C., et al. (2002). Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94:805-818.
25. Rosenberg, S. A., Yang, J. C., et al. (2003). Recombinant fowlpox viruses encoding the anchormodified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 9:2973-2980.
26. Schneider, J., Gilbert, S. C., et al. (1999). Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170:29-38.
27. Schumacher, R., Adamina, M., et al. (2004). Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 22:714-723.
28. Schumacher, R., Amacker, M., et al. (2005). Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine 23:5572-5582.
29. Schumacher, R., Spagnoli, G. C., Adamina, M. (2006). Influenza virosomes as adjuvants in Cancer Immunotherapy. In Gregoriadis G., ed. Liposome Technology. New York: Taylor & Francis CRC Press. 3rd edition, Volume II: in press.
30. Schwaninger, R., Waelti, E., et al. (2004). Virosomes as new carrier system for cancer vaccines. Cancer Immunol. Immunother. 53:1005-1017.
31. Singh M., O'Hagan, D. (1999). Advances in vaccine adjuvants. Nat. Biotechnol. 17: 1075-1081.
32. Tartaglia, J., Bonnet, M. C., et al. (2001). Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 19:2571-2575.
33. Thurner, B., Haendle, I., et al. (1999). Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669-1678.
34. van der Bruggen, P., Traversari, C., et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647.
35. Weber, J., Sondak, V. K., et al. (2003). Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97:186-200.
36. World Health Organization. (2005). Evidence and Information for Health Policy. WHO Statistical Information System. http://www3.who.int/whosis/menu.cfm.
37. Zajac, P., Oertli, D., et al. (2003). Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther. 14:1497-1510.